Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 1
1956 1
1957 2
1958 3
1959 1
1961 2
1962 5
1963 4
1964 1
1965 8
1966 2
1967 6
1968 2
1969 8
1970 1
1971 8
1972 5
1974 7
1975 6
1976 8
1977 3
1978 11
1979 9
1980 4
1981 5
1982 9
1983 11
1984 17
1985 13
1986 11
1987 9
1988 15
1989 12
1990 16
1991 17
1992 19
1993 17
1994 17
1995 26
1996 17
1997 16
1998 27
1999 33
2000 22
2001 20
2002 19
2003 27
2004 33
2005 29
2006 27
2007 44
2008 41
2009 50
2010 45
2011 46
2012 45
2013 33
2014 33
2015 41
2016 50
2017 58
2018 50
2019 61
2020 70
2021 96
2022 81
2023 83
2024 69
2025 88
2026 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,529 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Kitajima T, Moonka D, Yeddula S, Collins K, Rizzari M, Yoshida A, Abouljoud MS, Nagai S. Kitajima T, et al. Among authors: nagai s. Liver Transpl. 2021 Aug;27(8):1217-1218. doi: 10.1002/lt.26058. Epub 2021 Jul 20. Liver Transpl. 2021. PMID: 33786986 No abstract available.
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y, Nomoto H, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H; SWITCH-SEMA 1 study group. Takahashi Y, et al. Among authors: nagai s. Diabetes Obes Metab. 2023 Jun;25(6):1503-1511. doi: 10.1111/dom.14998. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36722623 Free article. Clinical Trial.
Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition.
Xi Q, Kunita A, Ogawa M, Ka M, Tanimoto S, Tsuchimochi S, Nagai S, Matsunaga A, Fukuda T, Watanabe K, Sone K, Shinozaki-Ushiku A, Kawana K, Ushiku T, Osuga Y, Katayama K, Kage H, Oda K. Xi Q, et al. Among authors: nagai s. Oncogene. 2025 May;44(19):1375-1386. doi: 10.1038/s41388-025-03312-4. Epub 2025 Feb 24. Oncogene. 2025. PMID: 39994376 Free PMC article.
Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study.
Nozawa K, Iwata H, Mukohara T, Taira T, Yoshimura A, Nagai SE, Hashimoto J, Matsuura K, Mizuno T, Shinden Y, Yamamoto M, Takano T, Wakahara M, Terakawa H, Yamanaka T, Kojima Y, Nakayama T, Hirakawa Y, Kuge K, Tanabe A, Tsurutani J. Nozawa K, et al. Among authors: nagai se. ESMO Open. 2025 Aug;10(8):105511. doi: 10.1016/j.esmoop.2025.105511. Epub 2025 Jul 25. ESMO Open. 2025. PMID: 40714515 Free PMC article.
Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).
Nagai SE, Hattori M, Yoshinami T, Masuda H, Okamura T, Watanabe K, Nakayama T, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Sasada S, Ishida T, Futamura M, Muramatsu Y, Kosaka N, Masuda N. Nagai SE, et al. Breast Cancer. 2025 Jul;32(4):705-715. doi: 10.1007/s12282-025-01689-4. Epub 2025 Apr 5. Breast Cancer. 2025. PMID: 40186791 Free PMC article.
mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer.
Tamura T, Nagai S, Masuda K, Imaeda K, Sugihara E, Yamasaki J, Kawaida M, Otsuki Y, Suina K, Nobusue H, Akahane T, Chiyoda T, Kisu I, Kobayashi Y, Banno K, Sakurada K, Okita H, Yamaguchi R, Ahmed AA, Yamagami W, Saya H, Aoki D, Nagano O. Tamura T, et al. Among authors: nagai s. Cancer Lett. 2025 Apr 28;616:217565. doi: 10.1016/j.canlet.2025.217565. Epub 2025 Feb 17. Cancer Lett. 2025. PMID: 39971122 Free article.
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.
Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, Ishihara M, Yamanaka T, Ozaki Y, Hara F, Nakamura R, Hattori M, Miyashita M, Kondo N, Yoshinami T, Takada M, Matsumoto K, Narui K, Sasada S, Iwamoto T, Hosoda M, Takano Y, Oba T, Sakai H, Murakami A, Higuchi T, Tsuchida J, Tanabe Y, Shigechi T, Tokuda E, Harao M, Kashiwagi S, Mase J, Watanabe J, Nagai SE, Yamauchi C, Yamamoto Y, Iwata H, Saji S, Toyama T. Terada M, et al. Among authors: nagai se. Breast Cancer. 2023 Nov;30(6):872-884. doi: 10.1007/s12282-023-01505-x. Epub 2023 Oct 7. Breast Cancer. 2023. PMID: 37804479 Free PMC article.
Lung function decline in sarcoidosis.
Tanizawa K, Handa T, Nagai S, Ikezoe K, Kubo T, Yokomatsu T, Ueda S, Fushimi Y, Ogino S, Watanabe K, Nakatsuka Y, Hirai T, Izumi T. Tanizawa K, et al. Among authors: nagai s. Respir Investig. 2022 Jul;60(4):551-561. doi: 10.1016/j.resinv.2022.02.009. Epub 2022 Apr 7. Respir Investig. 2022. PMID: 35400618
1,529 results